20Med Therapeutics has an open PhD position in the ITN CARTHAGO program aimed at developing non-viral gene therapy for the treatment of osteoarthritis.
Leiden, The Netherlands, October 1, 2020, 20Med Therapeutics today announced its involvement in the EC funded Horizon 2020 Marie Curie Innovative Training Network (ITN) CARTHAGO project. CARTHAGO offers 15 PhD positions with different partners across Europe. One PhD candidate will design and develop polymeric nanoparticles together with the 20Med development team for optimization of oligonucleotide delivery to cartilage cells and tissues. The oligonucleotide loaded nanoparticles will be used to induce regeneration of cartilage tissue and the efficacy of the oligonucleotide delivery and treatment in vitro and in vivo disease models will be evaluated. Cell and animal experiments will be executed in collaboration with the University Medical Center Utrecht (UMCU). This project is focused on preparation and in vitro and in vivo evaluation of the biomolecular designs for improved treatment of osteoarthritis using non-viral gene therapy.
Osteoarthritis, which affects 130 million people worldwide, is characterized by chronic joint pain and functional impairment. OA imposes a huge burden on the individual patient and European health care system. No treatments for OA are available to counteract disease progression. Often total joint replacement is the only therapeutic option.
About 20Med Therapeutics:
20Med Therapeutics is a Dutch biotechnology company applying innovative nanotechnology for the development of RNA therapeutics. Our delivery platform is based on bioresponsive polymers specifically designed for the efficient intracellular delivery of oligonucleotides. The nanoparticles are widely applicable for the delivery of oligonucleotide-based therapeutics using various routes of administration. 20Med has offices and laboratories in Leiden and Enschede.
About the CARTHAGO programme:
The EC funded Horizon 2020 Marie Curie Innovative Training Network (ITN) CARTHAGO project is an international PhD programme on non-viral gene therapy in regenerative medicine for osteoarthritis and intervertebral disc degeneration coordinated by the University Medical Center Utrecht (UMCU). Together with 8 academic and 4 non-academic partners across 10 EU countries, it offers a unique opportunity to excellent PhD candidates (early stage researchers, ESRs) to to gain experience and skills with short-term selected secondments within a world class consortium.
For more information, visit: https://itn-carthago.sites.uu.nl/esr3-20med-netherlands/
Apply here: https://itn-carthago.sites.uu.nl/apply-now/
Inquiries
20Med Therapeutics BV
info@20medtx.com